文献速递食管胃疾病与幽门螺杆菌

伏诺拉生-阿莫西林双联方案不同剂量与疗程根除幽门螺杆菌的疗效与安全性

Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-02-01

该多中心前瞻性随机对照非劣效性试验纳入516例初治幽门螺杆菌感染患者,比较三种伏诺拉生-阿莫西林双联方案。结果显示高剂量阿莫西林10天与14天方案根除率相当且非劣效,而低剂量阿莫西林10天方案根除率较低。各组不良事件及退出率相似。

要点

  • 高剂量阿莫西林10天方案非劣效于14天方案
  • 低剂量阿莫西林10天方案根除率较低
  • 各组安全性与依从性相似

核心结论

  • 高剂量阿莫西林10天和14天伏诺拉生双联方案根除幽门螺杆菌疗效满意,低剂量阿莫西林10天方案劣于14天方案。

研究设计与样本

  • 多中心、前瞻性、随机对照、非劣效性试验,纳入5个临床中心的初治幽门螺杆菌感染患者,共随机516例。

主要发现

  • 各组研究退出率、失访率和不良事件发生率相似。

关键数值与推荐

  • H-VA-10方案:伏诺拉生20 mg每日两次+阿莫西林750 mg每日四次,疗程10天。
  • L-VA-10方案:伏诺拉生20 mg每日两次+阿莫西林1000 mg每日两次,疗程10天。
  • H-VA-14方案:伏诺拉生20 mg每日两次+阿莫西林750 mg每日四次,疗程14天。
  • 根除率于治疗结束后至少28天通过13C-尿素呼气试验评估。

临床怎么用

  • 可考虑选用高剂量阿莫西林10天伏诺拉生双联方案作为初治幽门螺杆菌感染的根除方案。
  • 低剂量阿莫西林10天方案根除率较低,不推荐优先使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Previous studies confirm vonoprazan-amoxicillin effectiveness for Helicobacter pylori. This study aims to investigate vonoprazan with varying amoxicillin dose and duration. METHODS: This multicenter, prospective, randomized controlled, noninferiority trial enrolled patients with treatment naive H pylori infection from 5 clinical centers. Eligible participants were randomly assigned to H-VA-10 (vonoprazan 20 mg twice a day (b.i.d.) + amoxicillin 750 mg 4 times a day, 10 days), L-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 1000 mg b.i.d, 10 days), and H-VA-14 (vonoprazan 20 mg b.i.d + amoxicillin 750 mg 4 times a day, 14 days) in a 1:1:1 ratio. The eradication rate was assessed using the 13C-urea breath test at least 28 days after treatment. RESULTS: Of the 623 eligible patients, 516 patients were randomized. In both the intention-to-treat and per-protocol analyses, eradication rates were comparable between H-VA-10 and H-VA-14 groups (86.6% vs 89.5% and 90.9% vs 94.5%, P = .021 and .013 for noninferiority, respectively). However, eradication rates were significantly lower in the L-VA-10 group than the H-VA-14 group (79.7% vs 89.5% and 82.0% vs 94.5%, P = .488 and .759, respectively). Rates of study withdrawal, loss to follow-up, and adverse events were similar across study groups. CONCLUSIONS: H-VA-10 and H-VA-14 regimens provide satisfactory efficacy for H pylori infection, and the L-VA-10 regimen was inferior. CLINICALTRIALS: gov number: NCT05719831.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Peng X, Yao JY, Ma YQ, et al. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study. Clin Gastroenterol Hepatol. 2024. PMID: 38309492. doi:10.1016/j.cgh.2024.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。